ArticleJournal of food and drug analysis2014
Formulation and evaluation of controlled-release of telmisartan microspheres: In vitro/in vivo study.
Article in Journal of food and drug analysis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Extraction, Characterization, and Evaluation ofAdvances in pharmacological and pharmaceutical sciences · 2023Article
- Photoprotection and Photostability of a New Lignin-Gelatin-Antioxidants (Basel, Switzerland) · 2021Article
- Green Extraction by Ultrasound, Microencapsulation by Spray Drying and Antioxidant Activity of the Tucuma Coproduct (Biomolecules · 2021Article
- Statistically optimized pentazocine loaded microsphere for the sustained delivery application: Formulation and characterization.PloS one · 2021Article
- Transdermal Delivery of Telmisartan: Formulation, in vitro, ex vivo, Iontophoretic Permeation Enhancement and Comparative Pharmacokinetic Study in Rats.Drug design, development and therapy · 2021Article
- Proniosomal Telmisartan Tablets: Formulation, in vitro Evaluation and in vivo Comparative Pharmacokinetic Study in Rabbits.Drug design, development and therapy · 2020Article
- Application of statistical design to evaluate critical process parameters and optimize formulation technique of polymeric nanoparticles.Royal Society open science · 2019Article
- Triple-component nanocomposite films prepared using a casting method: Its potential in drug delivery.Journal of food and drug analysis · 2018Article
- Formulation and evaluation of pH-sensitive rutin nanospheres against colon carcinoma using HCT-116 cell line.Journal of advanced research · 2018Article
- New ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of irbesartan in human plasma.Journal of food and drug analysis · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this work was to design a controlled-release drug-delivery system for the angiotensin-II receptor antagonist drug telmisartan. Telmisartan was encapsulated with different EUDRAGIT polymers by an emulsion solvent evaporation technique and the physicochemical properties of the formulations were characterized. Using a solvent evaporation method, white spherical microspheres with particle sizes of 629.9-792.1 μm were produced. The in vitro drug release was studied in three different pH media (pH 1.2 for 2 hours, pH 6.8 for 4 hours, and pH 7.4 for 18 hours). The formulations were then evaluated for their pharmacokinetic parameters. The entrapment efficiency of these microspheres was between 58.6% and 90.56%. The obtained microspheres showed good flow properties, which were evaluated in terms of angle of repose (15.29-26.32), bulk and tapped densities (0.37-0.53 and 0.43-0.64, respectively), Carr indices and Hausner ratio (12.94-19.14% and 1.14-1.23, respectively). No drug release was observed in the simulated gastric medium up to 2 hours; however, a change in pH from 1.2 to 6.8 increased the drug release. At pH 7.4, formulations with EUDRAGIT RS 100 showed a steady drug release. The microsphere formulation TMRS-3 (i.e., microspheres containing 2-mg telmisartan) gave the highest C
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.